Arcutis Biotherapeutics filed a supplemental New Drug Application with the U.S. Food and Drug Administration to extend the approved use of its topical phosphodiesterase‑4 inhibitor ZORYVE® (roflumilast) cream 0.05% to infants as young as three months with mild‑to‑moderate atopic dermatitis.
The submission is backed by a Phase 1 pharmacokinetic study and a Phase 2 open‑label trial (INTEGUMENT‑INFANT) that enrolled 101 infants. Once‑daily application of the cream was well tolerated, with a 34.4 % rate of validated Investigator Global Assessment success (clear or almost clear) at week 4 and a 49 % success rate in the overall cohort. Safety data were consistent with the drug’s profile in older children, and no new safety signals emerged.
The infant eczema market is estimated at $1.5 billion in the United States, with up to 60 % of children developing symptoms within their first year. Current steroid‑free topical options are scarce, making ZORYVE’s steroid‑free, non‑greasy formulation a potentially first‑in‑class solution for this vulnerable population.
ZORYVE is one of only two FDA‑approved non‑steroidal topical agents for atopic dermatitis. Its unique profile—formulated without propylene glycol or alcohols—positions it favorably against existing treatments that rely on topical steroids or have limited pediatric data.
Arcutis’ Q4 2025 earnings beat expectations, reporting revenue of $129.5 million and an EPS of $0.13 versus analyst estimates of $0.08. The company raised its 2026 product revenue guidance to $480–$495 million in February 2026, reflecting confidence in ZORYVE’s commercial momentum and the potential impact of the infant indication.
Frank Watanabe, president and CEO, said the sNDA submission represents an important milestone in expanding treatment options for infants, emphasizing the potential to provide a steroid‑free, well‑tolerated therapy that could reduce cumulative steroid exposure and reinforce ZORYVE’s role as a foundational therapy across age groups.
The American Academy of Dermatology’s first‑ever pediatric atopic dermatitis guidelines, published in April 2026, gave ZORYVE a strong recommendation, underscoring its clinical credibility in the pediatric population.
The announcement was welcomed by investors and analysts, who noted the opportunity to capture a significant share of the infant eczema market and the strategic importance of expanding ZORYVE’s age range.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.